619 results on '"Patriarca, F"'
Search Results
2. Nilotinib in steroid-refractory cGVHD: prospective parallel evaluation of response, according to NIH criteria and exploratory response criteria (GITMO criteria)
3. The Italian CART‐SIE real life multicenter observational study on Chimeric Antigen Receptor T‐cell (CAR‐T) therapy for large B‐cell (LBCL) and mantle cell (MCL) lymphomas
4. P20 LENALIDOMIDE MAINTENANCE AFTER VTD INDUCTION AND AUTOLOGOUS STEM CELL TRANSPLANTATION: PRELIMINARY RESULTS OF A REAL-LIFE STUDY INCLUDING 389 PATIENTS
5. P49 A REAL-WORLD RETROSPECTIVE-PROSPECTIVE ANALYSIS OF EFFICACY AND SAFETY OF COMBINED IXAZOMIB, LENALIDOMIDE AND DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA: THE NORTHERN ITALY EXPERIENCE
6. P39 DEDALO: PHASE II STUDY OF DARATUMUMAB PLUS POMALIDOMIDE AND DEXAMETHASONE (DPD) IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA AND 17P DELETION
7. P07 BORTEZOMIB-MELPHALAN-PREDNISONE (VMP) VS. LENALIDOMIDE-DEXAMETHASONE (RD) IN REAL-LIFE MULTIPLE MYELOMA PATIENTS INELIGIBLE FOR TRANSPLANT: UPDATED ANALYSIS OF THE RANDOMIZED PHASE IV REAL MM TRIAL
8. Distribution and growth. A dynamic approach
9. ‘Real-life’ report on the management of chronic GvHD in the Gruppo Italiano Trapianto Midollo Osseo (GITMO)
10. Busulfan or Treosulfan Conditioning Platform for Allogeneic Stem Cell Transplantation in Patients Aged >60 Y With Acute Myeloid Leukemia/Myelodysplastic Syndrome: A Subanalysis of the GITMO AlloEld Study
11. Autologous transplant vs oral chemotherapy and lenalidomide in newly diagnosed young myeloma patients: a pooled analysis
12. Factors predicting outcome after allogeneic transplant in refractory acute myeloid leukemia: a retrospective analysis of Gruppo Italiano Trapianto di Midollo Osseo (GITMO)
13. Prospective molecular monitoring of minimal residual disease after non-myeloablative allografting in newly diagnosed multiple myeloma
14. 18F-FDG PET/CT focal, but not osteolytic, lesions predict the progression of smoldering myeloma to active disease
15. PB1984: ELOTUZUMAB PLUS LENALIDOMIDE AND DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA: EXTENDED 3-YEAR FOLLOW-UP OF AN ITALIAN, MULTICENTER, EXPERIENCE OUTSIDE OF CONTROLLED CLINICAL TRIALS
16. Successful mobilization of PBSCs predicts favorable outcomes in multiple myeloma patients treated with novel agents and autologous transplantation
17. Gender associated circadian oscillations of the clock genes in rat choroid plexus
18. Sirolimus-based graft-versus-host disease prophylaxis promotes the in vivo expansion of regulatory T cells and permits peripheral blood stem cell transplantation from haploidentical donors
19. Bortezomib-thalidomide-dexamethasone (VTD) is superior to bortezomib-cyclophosphamide-dexamethasone (VCD) as induction therapy prior to autologous stem cell transplantation in multiple myeloma
20. Intensified chemo-immunotherapy with or without stem cell transplantation in newly diagnosed patients with peripheral T-cell lymphoma
21. Comparative evaluation of biological HLA-DPB1 mismatch models for survival and graft versus host disease prediction after unrelated donor hematopoietic cell transplantation
22. Cytomegalovirus Prophylaxis versus Pre-emptive Strategy: Different CD4+ and CD8+ T Cell Reconstitution after Allogeneic Hematopoietic Stem Cell Transplantation: CMV Pre-emptive Treatment versus Prophylaxis
23. Allogeneic transplantation following a reduced-intensity conditioning regimen in relapsed/refractory peripheral T-cell lymphomas: long-term remissions and response to donor lymphocyte infusions support the role of a graft-versus-lymphoma effect
24. Refractory and 17p-deleted chronic lymphocytic leukemia: improving survival with pathway inhibitors and allogeneic stem cell transplantation
25. Stem cell mobilization in patients with newly diagnosed multiple myeloma after lenalidomide induction therapy
26. Kinetics of Th1/Th2 cytokines and lymphocyte subsets to predict chronic GVHD after allo-SCT: results of a prospective study
27. COMPARISON OF DIFFERENT STRATEGIES OF MINIMAL RESIDUAL DISEASE DETECTION AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR ACUTE LEUKEMIA: PH-AB259
28. SECOND ALLOGRAFT FOR RELAPSE AFTER ALLOGENEIC STEM CELL TRANSPLANTATION: A RETROSPECTIVE ANALYSIS OF 17 PATIENTS: PH-AB173
29. POSTALLOGRAFT LENALIDOMIDE AS SALVAGE TREATMENT: A RETROSPECTIVE ANALYSIS OF 13 PATIENTS: PH-AB172
30. POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN A PATIENT WITH CHRONIC MYELOID LEUKEMIA: PH-AB095
31. PERSISTENCE OF EXTRAMEDULLARY DISEASE BY PET/CT IS AN INDEPENDENT PREDICTOR OF ADVERSE OUTCOME AFTER ALLOGENEIC TRANSPLANT IN MULTIPLE MYELOMA: PH-P515
32. HIGH-DOSE RITUXIMAB IN THE CONDITIONING REGIMEN BEFORE ALLOGENEIC STEM CELL TRANSPLANTATION FOR RELAPSED B-CELL LYMPHOMAS IS ASSOCIATED WITH REDUCED GVHD-RELATED DEATHS, BUT DID NOT IMPROVE DISEASE CONTROL: PH-P393
33. EXTRACORPOREAL PHOTOPHERESIS IN ACUTE GRAFT-VERSUS-HOST DISEASE: CLINICAL OUTCOME, SURVIVAL AND STEROID SPARING EFFECT IN 20 PATIENTS TREATED OVER A 6-YEAR PERIOD: PH-P389
34. IMPACT OF HLA-DISPARITY DEGREE ON B-CELL RECONSTITUTION AFTER UNRELATED STEM CELL TRANSPLANTATION FOR ACUTE LEUKEMIA: PH-P302
35. CLOFARABINE AND TREOSULFAN IN CONDITIONING FOR ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANT FROM MATCHED DONORS: A MULTICENTRIC PHASE II STUDY: PH-P103
36. DONOR LYMPHOCYTE INFUSION FOR AFTER ALLOGENEIC STEM CELL TRANSPLANTATION: A RETROSPECTIVE ANALYSIS OF 57 PATIENTS.: PH-P075
37. The hematopoietic cell transplantation comorbidity index (HCT-CI) predicts clinical outcomes in lymphoma and myeloma patients after reduced-intensity or non-myeloablative allogeneic stem cell transplantation
38. The CIBMTR score predicts survival of AML patients undergoing allogeneic transplantation with active disease after a myeloablative or reduced intensity conditioning: a retrospective analysis of the Gruppo Italiano Trapianto Di Midollo Osseo
39. Allogeneic stem cell transplantation following reduced-intensity conditioning can induce durable clinical and molecular remissions in relapsed lymphomas: pre-transplant disease status and histotype heavily influence outcome
40. Treatment of refractory chronic GVHD with rituximab: a GITMO study
41. Clinical features and survival of multiple myeloma patients harboring t(14;16) in the era of novel agents
42. Correction to: Market competition and parental background wage premium: the role of human and relational capital (The Journal of Economic Inequality, (2020), 18, 3, (291-317), 10.1007/s10888-020-09441-y)
43. Autologous haematopoietic stem-cell transplantation versus bortezomib–melphalan–prednisone, with or without bortezomib–lenalidomide–dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study
44. Incidence, outcome, and risk factors of late-onset noninfectious pulmonary complications after unrelated donor stem cell transplantation
45. Prognostic significance of the detection of tumour cells in peripheral blood stem cell collections in stage II and III breast cancer patients treated with high-dose therapy
46. The choroid plexus is a site of testosterone synthesis: SW04.S19–53
47. Prognostic factors and outcome of Epstein–Barr virus DNAemia in high-risk recipients of allogeneic stem cell transplantation treated with preemptive rituximab
48. Pre-emptive donor lymphocyte infusions after haploidentical stem cells transplantation favour long lasting remission in a case of advanced and refractory Hodgkinʼs disease: R1547
49. Meningeal and cerebral involvement in multiple myeloma patients
50. Long Term Follow Up of Allogeneic Peripheral Blood Stem Cell Donors: A Single Institution Experience on 190 Donors: SP508
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.